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Abstract 21 
Fish can be exposed to a variety of neuroactive pharmaceuticals via the effluent 22 
discharges from wastewater treatment plants and concerns have arisen regarding their 23 
potential impacts on fish behaviour and ecology. In this study, we investigated the uptake of 24 
14 neuroactive pharmaceuticals from a treated wastewater effluent into blood plasma and 25 
brain regions of roach (Rutilus rutilus) after exposure for 15 days. We show that a complex 26 
mixture of pharmaceuticals including, 6 selective serotonin reuptake inhibitors, a serotonin-27 
noradrenaline reuptake inhibitor, 3 atypical antipsychotics, 2 tricyclic antidepressants and a 28 
benzodiazepine, concentrate in different regions of the brain including the telencephalon, 29 
hypothalamus, optic tectum and hindbrain of effluent-exposed fish. Pharmaceuticals, with the 30 
exception of nordiazepam, were between 3-40 fold higher in brain compared with blood 31 
plasma, showing these neuroactive drugs are readily uptaken, into brain tissues in fish. To 32 
assess for the potential for any adverse ecotoxicological effects, the effect ratio was 33 
calculated from human therapeutic plasma concentrations (HtPCs) and the measured or 34 
predicted fish plasma concentrations of pharmaceuticals. After accounting for a safety factor 35 
of 1000, the effect ratios indicated that fluoxetine, norfluoxetine, sertraline, and amitriptyline 36 
warrant prioritisation for risk assessment studies. Furthermore, although plasma 37 
concentrations of all the pharmaceuticals were between 33 to 5714-fold below HtPCs, 38 
alterations in serotonin, glutamate, acetylcholine and tryptophan concentrations were 39 
observed in different brain regions of effluent-exposed fish. This study highlights the 40 
importance of determining the potential health effects arising from the concentration of 41 
complex environmental mixtures in risk assessment studies.  42 
 43 
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1. Introduction 46 
After human ingestion, many pharmaceuticals are excreted in their native form or as 47 
metabolites and they enter aquatic systems mainly via effluents from wastewater treatment 48 
works (WwTWs) (Fent et al., 2006; Gardner et al., 2012; Kostich et al., 2014; Petrie et al., 49 
2015; Tanoue et al., 2015). Recently, concerns have arisen regarding the presence of 50 
neuroactive pharmaceuticals, such as selective serotonin reuptake inhibitors (SSRIs) and 51 
benzodiazepines, in WwTW effluents because these pharmaceuticals have been shown to 52 
alter behaviour of different fish species under experimental laboratory conditions (Brodin et 53 
al., 2013; Huerta et al., 2016; Margiotta-Casaluci et al., 2014; Valenti et al., 2012). In 54 
addition to SSRIs, other types of antidepressants including serotonin-noradrenaline reuptake 55 
inhibitors (SNRIs) and tricyclic antidepressants are also regularly detected in effluents from 56 
WwTWs (Grabicova et al., 2014; Lajeunesse et al., 2011; Petrie et al., 2015). In comparison 57 
to SSRIs, the effects of tricyclic antidepressants on fish behaviour have been less studied, but 58 
a member of this class, amitriptyline, is extensively prescribed in England to treat depression 59 
and psychiatric disorders (>10,000 kg in England in 2012) (Petrie et al., 2015; Ziarrusta et al., 60 
2017).  61 
Recent studies investigating the effects of neuroactive pharmaceuticals on fish have 62 
focused on behavioural endpoints as these are likely to be the primary effects of exposure to 63 
neuroactive pharmaceuticals according to the read-across hypothesis (Margiotta-Casaluci et 64 
al., 2014; Valenti et al., 2012). This hypothesis has been suggested to be a useful tool in risk 65 
assessment studies and is based on the theory that blood plasma concentrations of 66 
pharmaceuticals in non-target vertebrates similar to human therapeutic plasma concentrations 67 
are likely to cause pharmacological effects in organisms such as fish (Huggett et al., 2003; 68 
Rand-Weaver et al., 2013). However, there is uncertainty as to whether environmental water 69 
concentrations of neuroactive drugs such as SSRIs bioconcentrate to high enough 70 
concentrations in the plasma or target tissues to cause behavioural effects in fish (Sumpter et 71 
al., 2014). Mean measured concentrations of neuroactive pharmaceuticals in WwTW 72 
effluents have been reported at between 1 and 330 ng/L for SSRIs (e.g., fluoxetine, sertraline 73 
and citalopram), SNRIs (venlafaxine), tricyclic antidepressants (amitriptyline) and 74 
benzodiazepines (diazepam) (Grabicova et al., 2014; Petrie et al., 2015), and these are far 75 
below water concentrations for SSRIs fluoxetine, sertraline and citalopram (in the range of 1-76 
116 µg/L) and for venlafaxine (between 250 and 500 µg/L) reported to affect the behaviour 77 
of different fish species in laboratory experiments (Bisesi et al., 2014; Kellner et al., 2016; 78 
Margiotta-Casaluci et al., 2014; Valenti et al., 2012; Xie et al., 2015). In contrast with these 79 
reports however, there have been some studies indicating that fluoxetine at concentrations 80 
below 1 µg/L (0.3 µg/L and 0.54 µg/L), and therefore similar to environmental 81 
concentrations, could affect fish behaviour (Barry, 2013; Dzieweczynski and Hebert, 2012). 82 
Furthermore, non-monotonic shifts in behavioural responses have been reported for 83 
neuroactive compounds such as oxazepam (Huerta et al., 2016). More information is needed 84 
on the uptake and tissue partitioning of mixtures of neuroactive pharmaceuticals in fish to 85 
support the environmental risk assessments of these drugs in aquatic environments.  86 
In a recent study, we used a holistic untargeted chemical profiling approach to identify 87 
pharmaceuticals accumulating in roach (Rutilus rutilus) exposed to a treated wastewater 88 
effluent. We identified 14 different neuroactive compounds in extracts of either gonad, liver, 89 
gills, kidney or plasma (David et al., 2017). The aim of the study presented here was to use 90 
targeted analyses to quantify the concentrations of this pharmaceutical mixture in plasma and 91 
brain and investigate for biological responses in the brain via measurement of 92 
neurotransmitter concentrations as a consequence of effluent exposure. We provide novel 93 
information on the accumulation pattern of neuroactive pharmaceuticals in four different 94 
regions of the brain, i.e. the telencephalon, hypothalamus, optic tectum and hindbrain. We 95 
show that even though plasma concentrations of all neuroactive drugs were well below the 96 
human therapeutic plasma concentrations, concentrations of neurotransmitters were altered in 97 
the hypothalamus of effluent-exposed fish, highlighting the need to understand the effects of 98 
exposure to complex chemical mixtures on fish behaviour and physiology. 99 
2. Materials and Methods 100 
2.1 Chemicals and reagents  101 
Certified standards of glutamate, acetylcholine, serotonin, tryptophan, fluoxetine 102 
(Fluo), sertraline (Ser), paroxetine (Par), clozapine (Clo), venlafaxine (Venlaf), and also 103 
formic acid, ammonium hydroxide, phosphoric acid were obtained from Sigma Aldrich, 104 
Dorset, UK. Norfluoxetine (norFluo), norsertraline (norSer), citalopram (Cit), norclozapine 105 
(norClo), quetiapine (Quet), amitriptyline (Ami), noramitriptyline (norAmi), diazepam 106 
(Diaz), nordiazepam (norDaz), serotonin-d4, norfluoxetine-d6 were purchased from LGC 107 
standards UK. Venlafaxine-d6, fluoxetine-d5 were purchased from QMX Laboratories 108 
Limited UK. All standards were > 99% compound purity and deuterated standards > 97% 109 
isotopic purity. HPLC grade acetonitrile, methanol and water were obtained from Rathburns 110 
UK. Oasis HLB cartridges (1 g) were obtained from Waters, Manchester, UK and Strata-X-C 111 
Polymeric Reversed Phase 96-Well Plates (33 μm sized particles, 30 mg/well) from 112 
Phenomenex, Macclesfield UK. 113 
 114 
2.2 Fish exposure and sample collections 115 
A population of male and female sexually mature roach (Rutilus rutilus, age 2+, mean 116 
± SEM length of 14.5 ± 1.3 cm and weight 45.4 ± 12.1 g) was exposed for 15 days to either a 117 
treated effluent from a WwTW or to clean water for the control population (60 fish per 118 
treatment and 120 fish in total). The WwTW received 95% influent from domestic sources 119 
(population equivalent of 117,574) and 5% input from industrial wastewaters. The influent 120 
was treated by fine screens, chemically assisted settlement, biological aerated flooded filter 121 
processes and ultraviolet disinfection. The pH of the effluent was 7.3, concentrations of 122 
suspended solids 21 mg/L, biochemical oxygen demand 11 mg/L, chemical oxygen demand 123 
67 mg/L and total ammonia 29 mg/L during the exposure period (South West Water data). 124 
Roach were exposed in triplicate tanks (20 fish per 200 L tank) to either dechlorinated water 125 
or 100% final effluent for fifteen days. The flow rate was 10 L/min and the effluent and water 126 
was continually aerated. The fish were maintained at an average temperature of 12 ± 1 ºC for 127 
both treatments under a constant photo-period (15h light : 9h dark).  128 
After 15 days, fish were terminated using an overdose of phenoxyethanol and 129 
according to UK Home Office regulations and local ethical guidelines. Blood was collected 130 
from the caudal vein using heparinised needles (BD Microlance 3 25G 0.5 x 25 mm), 131 
centrifuged (5 min, 10,000 g) and the plasma supernatant stored at -70 
o
C. Four different 132 
parts of the brain, i.e. the telencephalon, the hypothalamus, the optic tectum and the hindbrain 133 
were carefully dissected and immediately snap frozen in liquid nitrogen. All samples were 134 
stored at −70 °C until analysis. 135 
Wastewater effluent samples (2 x 2.5 litres) were collected in solvent washed, acid 136 
rinsed amber glass bottles at the beginning of the fish exposure (day 0), after 7 days, and at 137 
the end of the exposure period (day 15) in order to monitor the concentrations of neuroactive 138 
pharmaceuticals in the wastewater effluent throughout the exposure period. Samples were 139 
stored at 4°C with the addition of acetic acid (1%) and methanol (5%) and were extracted 140 
within 12 h after collection. 141 
 142 
2.2 Sample preparation 143 
2.2.1 Brain tissues and plasma samples 144 
Telencephalon (mean ± standard deviation; 18±4 mg), hypothalamus (15±3 mg), 145 
hindbrain (56±8 mg) and optic tectum (80±10 mg) tissues were extracted in glass tubes with 146 
300 µL of methanol and using a Microson XL2000 ultrasonic probe (Misonix Farmingdale) 147 
(10W x 40s). Before extraction, the mix of internal standards (IS) (serotonin-d4, venlafaxine-148 
d6, fluoxetine-d5 and norfluoxetine-d6) was added to each tissue sample. The amount of IS 149 
added were adjusted to the initial mass of tissue used so that the amount of each IS 150 
corresponded to 1.5 ng/18 mg of telencephalon, 1.5 ng/15 mg of hypothalamus, 1.5 ng/50 mg 151 
of hindbrain and 1.5 ng/75 mg of optic tectum. After extraction, samples were transferred to 152 
clean centrifuge tubes, centrifuged (13,000 RCF, 10 min) and the supernatant collected. After 153 
addition of 1500 μL of ultra pure water and 36 μL of phosphoric acid, the samples were 154 
purified using the Strata-X-C SPE plates. Sorbents were conditioned with 1 mL methanol, 155 
equilibrated with 1 mL of 2% phosphoric acid in HPLC grade water prior to loading brain 156 
extracts onto the SPE wells. After a washing step using 1 mL HPLC grade water, sorbents 157 
were dried under vacuum for 15 min. Analytes were eluted  with 1 mL of 5% ammonium 158 
hydroxide in methanol. Eluates were evaporated to dryness, reconstituted in 50 µL of 80/20 159 
water/methanol (v/v) and stored at -20 °C until analysis.  160 
Plasma concentrations of the pharmaceuticals were measured for female fish where 161 
more volume of blood sample was available for chemical analyses. Plasma samples (150 µL) 162 
were spiked with 1 ng of the mix of IS and 300 µL of methanol and the mixture vortexed (1 163 
min) and centrifuged (13,000 RCF, 10 min). The supernatant was collected, 1500 µL of 164 
HPLC water and 36 μL of phosphoric acid were added and samples were purified using the 165 
Strata-X-C plates as decribed previously, reconstituted in 50 µL of 80/20 water/methanol 166 
(v/v) and stored at -20 °C until analysis. 167 
 168 
2.2.2 Wastewater effluent 169 
For each sample, one litre of wastewater containing 5% of methanol and 1% of acid 170 
acetic and spiked with the mix of IS was pre-filtered through glass wool and filter paper 171 
Whatman No1 (Whatman, Maidstone, UK). Samples were then extracted through an Oasis 172 
HLB (20 mL, 1 g) cartridge, which was pre-conditioned with 10 mL of methanol and 10 mL 173 
HPLC water. The cartridge was washed with 20 mL of distilled water and dried under 174 
vacuum. Analytes were eluted with 10 mL of methanol and 10 mL of ethyl acetate. Extracts 175 
were dried and reconstituted in 1 mL of methanol. 300 mL of the residue was purified using 176 
Strata-X-C plates described above and reconstituted to a final volume of 120 µL (80/20 177 
water/methanol (v/v)) and stored at -20 °C until analysis. 178 
 179 
2.3 UHPLC-ESI-MS/MS 180 
UHPLC-MS/MS analyses were carried out using a Waters Acquity UHPLC system 181 
coupled to a Quattro Premier triple quadrupole mass spectrometer from Micromass (Waters, 182 
Manchester, UK). Samples were separated using a reverse phase Acquity UHPLC BEH C18 183 
column (1.7 μm, 2.1 mm × 100 mm, Waters, Manchester, UK) fitted with a ACQUITY 184 
UHPLC BEH C18 VanGuard pre-column (130 Å, 1.7 µm, 2.1 mm x 5 mm, Waters, 185 
Manchester, UK) and maintained at 22 °C. Injection volume was 20 µL and mobile phase 186 
solvents were 94. 8% water, 5% ACN, 0.2% formic acid (A) and 99.8% ACN, 0.2% formic 187 
acid (B). Separation was achieved using a flow rate of 0.1 mL/min with the following A:B 188 
gradient; 100:0 to 64:36 in 6 min; from 64:36 to 20:80 at 15 min, from 20:80 to 100% B at 189 
15.01 min and held for 5 min prior to return to initial conditions and equilibration for 5 min.  190 
MS/MS was performed in the multiple reaction monitoring (MRM) using ESI in the 191 
positive mode. Two characteristic fragmentations of the protonated molecular ion [M+H]
+ 
192 
were monitored (one for quantification and the other one for confirmation). The declustering 193 
potential and collision energy were optimised for each analyte (Table S1). Other parameters 194 
were optimised as follows: capillary voltage −3.3 kV, extractor voltage 8 V, multiplier 195 
voltage 650 V, source temperature 100 
◦
C, desolvation temperature 300 
◦
C. Argon was used 196 
as collision gas (P collision cell: 3×10
-3
 mbar), and nitrogen was used as desolvation gas (600 197 
L/h). Data were acquired using MassLynx 4.1 and the quantification was carried out by 198 
calculating the response factor of neurotransmitters and pharmaceuticals to their respective 199 
IS. Concentrations were determined using a least-square linear regression analysis of the peak 200 
area ratio versus the concentration ratio of the analyte to the IS. In order to account for 201 
interferences with the matrix, calibration curves for the pharmaceuticals present in brain 202 
tissues and plasma analyses were made in the sample matrix using plasma and brain tissues 203 
collected from additional unexposed fish. A minimum of a six point calibration curve (R
2
> 204 
0.99) was used to cover the range of concentrations observed in the different matrices, within 205 
the linear range of the instrument. Calibration curves were prepared in solvent only to 206 
quantify neurotransmitters as these were naturally occurring at high concentrations in all 207 
brain tissues and not subject to matrix interference. Method detection and quantification 208 
limits (MDL and MQL, respectively) were determined from spiked samples which had been 209 
extracted using the Strata-X-C method. MDLs were determined as the minimum amount of 210 
analyte detected with a signal-to-noise ratio of 3 and MQLs as the minimum amount of 211 
analyte detected with a signal-to-noise ratio of 10 (Table S2). 212 
2.4 Plasma and brain bioconcentration factors 213 
For the purpose of our study, we defined plasma and brain bioconcentration factors 214 
(BCFs) of pharmaceuticals as the ratio of blood plasma or brain to water concentrations for 215 
the specified exposure time adopted (i.e. 15 days) for which we would expect equilibrium 216 
saturation to have been reached, based on studies in other freshwater fish such as Japanese 217 
medaka and channel catfish where equilibrium concentrations for fluoxetine (Paterson and 218 
Metcalfe, 2008) and for diazepam (Overturf et al., 2016) were reached within 2-3 days of 219 
exposure. BCFs were calculated as follows:   220 
BCF = Cplasma or brain / Cambient water 221 
Where Cplasma or brain and Cambient water are the chemical concentrations in plasma or brain of fish 222 
and in ambient water (i.e., the WwTW effluent), respectively. Cplasma and Cambient water were 223 
both expressed in ng/mL while Cbrain was expressed in ng/g (wet weight). Cambient water was 224 
calculated from the mean concentration of the 3 sampling time points (day 0, 7 and 15 days of 225 
the fish exposure period) and Cplasma and Cbrain were calculated from the average 226 
concentrations measured in plasma and the four parts of the brain respectively. To calculate 227 
the average concentrations measured in the four parts of the brain of the effluent-exposed 228 
fish, the total amount found in the four parts of the brain was first calculated and then divided 229 
by the total mass of brain tissues analysed for each individual fish. 230 
Predicted BCFplasma, were calculated using fish steady-state plasma concentration 231 
(FssPC) which can be predicted using the Fish Plasma Model as follows (Huggett et al., 232 
2003): 233 
FssPC = [water concentration, ng/mL] x Pb/w 234 
Pb/w corresponds to blood to water partition coefficient and can be calculated using the 235 
following equation: 236 
 Log Pb/w = 0.73 x Log D7.4 – 0.88 237 
In the last equation, Log D7.4 (i.e., Log D value at buffer pH of  7.4) was used instead of Log 238 
Kow as several studies have shown that the ambient pH significantly affects the ionization of 239 
the pharmaceuticals analysed in this study (Margiotta-Casaluci et al., 2014; Nallani et al., 240 
2016; Tanoue et al., 2015; Valenti et al., 2009). Log D7.4 were obtained from chemspider 241 
(http://www.chemspider.com/). 242 
2.5 Quality control 243 
One workup sample (i.e. extraction using extraction methods without a tissue/plasma 244 
sample) per batch of 12 samples was injected on the UHPLC-MS/MS at the beginning of the 245 
run to ensure that no contamination occurred during the sample preparation. Solvent samples 246 
(methanol:water, 20:80) were also injected between sample batches to rule out the possibility 247 
of any carryover in the UHPLC system that might affect adjacent results in analytical runs. 248 
Identities of detected neurotransmitters and pharmaceuticals were confirmed by comparing 249 
ratios of MRM transitions in samples with that of pure standards. Quality control samples 250 
(QCs, i.e., standard solutions) were injected before all sample batches to monitor sensitivity 251 
changes and every 12 samples to monitor the sensitivity changes during the analysis of each 252 
batch. Recovery experiments performed on spiked brain tissues (50 ng/g, n=4), plasma 253 
samples (10 ng/mL, n=4) and HPLC water (8.5 ng/mL, n=4) gave absolute recovery values 254 
ranging from 61 ± 7 to 107 ± 14% for neurotransmitters and pharmaceuticals (Table S3). 255 
None of the studied pharmaceuticals were detected in the samples from control fish. 256 
 257 
2.6 Statistical analysis 258 
All statistical analyses were carried out using GraphPad Prism 5 software. To 259 
compare pharmaceutical and neurotransmitter concentrations in males and females between 260 
treatments, 12 fish per treatment were analysed by taking randomly 4 fish (2 males and 2 261 
females) from each triplicate tank (n=3 for biological replicates per treatment and n=12 for 262 
analytical replicates). Data was tested for normality using the Shapiro-Wilk test.  Differences 263 
in pharmaceutical concentrations between effluent-exposed males and females in different 264 
parts of the brain were assessed by two-way analysis of variance (ANOVA) followed by a 265 
Bonferronì multiple comparison tests. One-way ANOVA followed by Bonferronì multiple 266 
comparison tests were used to compare pharmaceutical concentrations in the different parts of 267 
the brain of effluent-exposed male or female fish. Nonparametric Mann−Whitney (M−W) U 268 
tests were used to compare neurotransmitter concentrations between control and exposed 269 
males and females. Differences were considered statistically significant at p≤0.05. Statistical 270 
results for the different tests, including the value of the test, the degrees of freedom, and the 271 
p-values are provided in Table S5 (two-way ANOVA), S6 (one-way ANOVA, male), S7 272 
(one-way ANOVA, female) and S9 (Mann–Whitney U-tests). To perform the statistical 273 
analyses, all concentrations that were over the limits of detection (≥MDL) but below the 274 
limits of quantification (<MQL) were assigned the value considered as the MDL in each case. 275 
Concentrations below the MDL were considered to be zero.  276 
 277 
3. Results and Discussion. 278 
3.1. Concentrations of neuroactive pharmaceuticals in wastewater of effluent-exposed roach 279 
after 15 days of exposure. 280 
Thirteen of the 14 test pharmaceuticals (norclozapine excluded) were detected in the 281 
WwTW effluent sampled during the exposure period (Table 1). Mean concentrations ranged 282 
from 8.5±1.1 ng/L (paroxetine) to 374±44 ng/L (amitriptyline). Individual pharmaceutical 283 
concentrations measured in the WwTW effluent during the exposure period were in the same 284 
range as that reported in other WwTW effluents in the UK (i.e., between 10 and 500 ng/L) 285 
(Petrie et al., 2015). For example, mean concentrations of fluoxetine in our study were 62 ± 286 
5.6 ng/L compared with a median of 23 ng/L and 95 percentile of 69 ng/L for fluoxetine 287 
measured in a comprehensive study of 162 WwTW effluents in the UK (Gardner et al., 288 
2012).  Likewise, mean concentrations of norfluoxetine (37 ± 13 ng/L), venlafaxine (356 ± 289 
39 ng/L) and amitriptyline (374 ± 44 ng/L) in our study aligned with those measured in 290 
several other UK WwTW effluents (Petrie et al., 2015) indicating that our study effluent 291 
content of neuroactive pharmaceuticals was representative of UK WwTW effluents more 292 
widely.  293 
The detection of mixtures of SSRIs and other neuroactive compounds in WwTW 294 
effluents is of potential environmental concern because they have the potential to alter fish 295 
behaviour (Brodin et al., 2013; Margiotta-Casaluci et al., 2014; Valenti et al., 2009). 296 
However, concentrations of the SSRIs fluoxetine, sertraline and citalopram and the SNRI 297 
venlafaxine measured in the undiluted effluent in our study were well below nominal 298 
concentrations that have been shown to affect fish behaviour under experimental laboratory 299 
conditions. For instance, exposure to water concentrations of sertraline at > 3 μg/L were 300 
necessary to cause changes in shelter-seeking behaviour in adult male fathead minnows 301 
(Valenti et al., 2012) and shoaling activity in crucian carp (Xie et al., 2015). Similarly, other 302 
studies investigating the effects of exposure to fluoxetine, citalopram or venlafaxine have 303 
shown that behaviour-related changes in fish were only observed after exposure to 304 
concentrations in the μg/L range (Bisesi et al., 2014; Kellner et al., 2016; Margiotta-Casaluci 305 
et al., 2014). In contrast to a number of studies investigating exposure effects of SSRIs on 306 
fish behaviour, little is known on the potential behavioural effects of exposure to atypical 307 
antipsychotics such as clozapine or tricyclic antidepressants such as amitriptyline. In 308 
addition, risk assessment studies are  based on exposures to single chemicals and do not 309 
reflect the complex and diverse mixtures of neuroactive pharmaceuticals that fish are exposed 310 
to in WwTW contaminated waters as revealed in our study. 311 
 312 
 313 
 314 
 315 
Table 1. Pharmaceutical concentrations in wastewater effluent and bioconcentration factors (BCFs) in effluent-exposed fish.   316 
  [Effluent] [Fish plasma] BCFplasma BCFbrain [Brain]/ 
[Plasma] 
Pharmaceuticals 
Range 
(ng/L) 
Av ± SD 
(ng/L) 
Range 
(ng/mL) 
Av ± SD 
(ng/mL) measured predicted measured 
SSRIs  
        fluoxetine 54 - 72 62 ± 5.6 0.33 - 0.45 0.39 ± 0.04 6.3 2.5 68 9.7 
norfluoxetine 17 - 61 37 ± 13 0.43 - 0.83 0.53 ± 0.15 14 5.6 285 18 
sertraline 47 - 65 55 ± 5.6 0.5 - 1 0.76 ± 0.21 14 26 361 27 
norsertraline 215 - 311 260 ± 31 3.3 - 15 9.5 ± 4.7 37 15 1581 37 
citalopram 211 - 340 274 ± 39 <0.02
a
 - <0.05
b
 n.a. n.a. n.a. 1.6 n.a. 
paroxetine 6.6 - 9.8 8.5 ± 1.1 <0.17
a
 n.a. n.a. n.a. 67 n.a. 
Atypical antipsychotic 
        clozapine 20 - 30 25 ± 3.5 <0.07
a
 - <0.2
b
 n.a. n.a. n.a. 105 n.a. 
norclozapine <0.08
a
 
 
<0.33
a
 n.a. n.a. n.a. n.a. n.a. 
quetiapine 18 - 33 23 ± 6.2 <0.03
a
 - <0.1
b
 n.a. n.a. n.a. 157 n.a. 
Tricyclic antidepressants 
        amitriptyline 298 - 421 374 ± 44 0.90  - 2.2 1.5 ± 0.5 4.0 19 15 4.4 
noramitriptyline 31 - 49 43 ± 7.6 <0.20
b
 - 0.3 0.16 ± 0.1 3.7 6.1 42 14 
SNRI 
        venlafaxine 295 - 393 356 ± 39 0.03 - 0.1 0.07 ± 0.02 0.2 1.5 0.7 3.7 
Benzodiazepine 
        diazepam 10 - 26 19 ± 6.2 <0.02
a
 n.a. n.a. n.a. n.a. n.a. 
nordiazepam 56 - 96 77 ± 15 <0.50
b
 - 0.55 0.51 ± 0.01 6.6 9.3 2 n.a. 
Wastewater effluents were sampled at the beginning of the experiment, after 7 days and the end of the experiment. Samples were analysed in 317 
triplicates for each sampling point (n=9 in total). BCFbrain was calculated from the sum of concentrations measured in the brain regions.   
a
 = 318 
MDL values; 
b
 = MQL values, SD= standard deviation and  n.a. not applicable as concentrations in effluent, plasma or brain extracts were < 319 
MQL. For mean calculations, concentrations that were over the limits of detection (≥MDL) but below the limits of quantification (<MQL) were 320 
assigned the MDL value. Concentrations below the MDL were considered to be zero.321 
 15 
3.2. Concentrations of neuroactive pharmaceuticals in plasma and brain of effluent-exposed 322 
roach 323 
After a 15 day exposure to WwTW effluent, 11 of the 14 test compounds were 324 
detected in plasma, the exceptions being paroxetine, norclozapine and diazepam. No analytes 325 
were detected in plasma from control fish (Table 1). Citalopram, clozapine and quetiapine 326 
and noramitriptyline were present at concentrations below the MQL. Mean measured 327 
concentrations of all other analytes were between 0.07 ± 0.02 (venlafaxine) and 9.5 ± 4.7 328 
ng/mL (norsertraline).  For the analytes where plasma concentrations were above the MQL, 329 
the measured BCFsplasma ranged from 0.2 to 37, in agreement with the  BCFplasma values for 330 
SSRIs and venlafaxine from a previous exposure study in which rainbow trout were exposed 331 
to an undiluted (Swedish) WwTW effluent for 13 days (Grabicova et al., 2014). In our study, 332 
the measured BCFs were in the same order of magnitude but differed by between 2- to 7 -fold 333 
lower or higher compared to their predicted BCFplasma values (Table 1). A previous study 334 
(Margiotta-Casaluci et al., 2014) has reported an inter-individual variability up to 7.6-fold in 335 
drug uptake (water/plasma), which would suggest that the differences between measured and 336 
predicted BCFs in our study are within an acceptable level of accuracy. Possible reasons for 337 
the discrepancies between measured and predicted BCFplasma values for these 338 
pharmaceuticals, as well as for other xenobiotics, may involve water pH (Valenti et al., 339 
2009), routes of exposure other than via diffusion through the gills (e.g., the diet), the effects 340 
of uptake/elimination mechanisms at gill membranes, plasma protein binding, and/or hepatic 341 
clearance rates (Tanoue et al., 2015).  342 
Analysis of brain tissues of roach after a 15 day exposure to WwTW effluent revealed 343 
that 13 neuroactive pharmaceuticals were detected in the optic tectum, 11 in the hindbrain 344 
and 10 in both the telencephalon and the hypothalamus (Figure 1, Table S4). None of the 345 
 16 
pharmaceuticals were detected in brain regions of control fish. Diazepam was not detected in 346 
any of the brain tissues of effluent-exposed fish and its biologically active metabolite 347 
nordiazepam was only detected in the optic tectum but at concentrations below the MQL. 348 
Both diazepam and nordiazepam are rapidly metabolized in vertebrate tissues (Friedman et 349 
al., 1986) which may account for the low levels present in brain and plasma despite being 350 
present at a concentration of 19±6 ng/L ng/L (mean±SD) in the effluent. The highest 351 
concentrations of pharmaceuticals detected in brain tissues of male and female roach were 352 
norsertraline (459±89 ng/g in the hindbrain), followed by sertraline (21±6.9 ng/g in the optic 353 
tectum), norfluoxetine (14±2.5 ng/g in the telencephalon), norclozapine (9.4±5.8 ng/g in the 354 
hindbrain), amitriptyline (7.5±2.7 ng/g in the hindbrain), and fluoxetine (5.7±4 ng/g in the 355 
hindbrain) (Table S4). Mean concentrations of citalopram, paroxetine, venlafaxine and 356 
nordiazepam were ≤1 ng/g in all brain tissues. Paroxetine and nordiazepam were detected 357 
only in the optic tectum and not in other brain tissues. This was most likely because the 358 
greater mass of tissue available for the analysis of the optic tectum that was on average 1.4, 359 
4.4 and 5.3 times higher than for the hindbrain, the telencephalon and the hypothalamus, 360 
respectively, thus influencing the MDL. Likewise, the MDL for norclozapine was higher than 361 
that of the other compounds (Table S2) which may explain why it was only detected in the 362 
optic tectum and the hindbrain.  363 
These findings are in agreement with reports that fluoxetine, sertraline and their “nor” 364 
metabolites are common SSRIs detected in the brain of fish species collected in an effluent-365 
dominated stream in USA (Brooks et al., 2005), in the brain of carp collected in an effluent-366 
dominated river in Japan (Tanoue et al., 2015) and in the brain of brook rainbow exposed to a 367 
diluted effluent from a WwTW in Canada (Lajeunesse et al., 2011). Sertraline, as well as 368 
citalopram and venlafaxine were also detected in the brain of rainbow trout exposed to an 369 
undiluted WwTW effluent in Sweden (Grabicova et al., 2014) and the antidepressant 370 
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bupropion and the antipsychotic risperidone have been found to accumulate in the brain of 371 
round goby exposed to undiluted WwTW effluents in Canada (McCallum et al., 2017). Here 372 
we show that other neuroactive drugs including the antipsychotics clozapine, norclozapine 373 
and quetiapine as well as the tricyclic antidepressants amitriptyline and its ‘nor’ metabolite 374 
also bioaccumulate in fish brain together with SSRIs and venlafaxine.   375 
Accumulation of pharmaceuticals in the brain of effluent-exposed fish was not 376 
affected by sex except for norsertraline which was present at slightly higher concentrations 377 
(1.2-1.7-fold) in males compared with females  in the telencephalon, hypothalamus and optic 378 
tectum (p<0.05) but not in the hindbrain (Figure 1). Generally, profiles of the 379 
pharmaceuticals were similar between the different regions of the brain of effluent exposed 380 
fish. Direct comparison of the distribution of sertraline, norsertraline, norfluoxetine and 381 
quetiapine between brain regions was possible as they were present at concentrations above 382 
the MQL in all four brain regions. However, quetiapine concentrations in both sexes were 383 
significantly higher in the optic tectum, sertraline and norsertraline were generally lower in 384 
the telencephalon and norfluoxetine (females only) significantly higher in the telencephalon 385 
compared with other brain regions (p<0.05, See Figures S1 and S2). The relatively uniform 386 
concentrations of SSRIs in different regions of the human brain after autopsy has been 387 
reported previously indicating that there are little regional differences in their uptake and 388 
metabolism between brain compartments (Wille et al., 2009).  The ratios of concentrations of 389 
the demethylated ‘nor’ metabolites to the parent compound were measured for fluoxetine, 390 
sertraline and amitriptyline in the effluent samples and were close to the values reported in 391 
human plasma (Table S8). However, the same ratios measured in fish plasma and brain 392 
regions were consistently higher for fluoxetine and sertraline compared with the effluent 393 
indicating further metabolism to the ‘nor’ metabolite within the fish tissues.  394 
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  410 
Figure 1. Concentrations of neuroactive pharmaceuticals (ng/g; mean ± standard error) in the telencephalon (A), hypothalamus (B), optic tectum 411 
(C) and hindbrain (D) of effluent-exposed male and female fish. Brain tissue from 12 fish (6 males and 6 females) sampled from three replicate 412 
tanks (2 males and 2 females per tank) were analysed. None of the studied pharmaceuticals were detected in the control fish. * significant 413 
difference between male and female fish p≤0.05. Fluo= fluoxetine, norFluo= norfluoxetine, sertraline, norSer= norsertraline, Cit= citalopram, 414 
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Par= paroxetine, Clo= clozapine, norClo=norclozapine, Quet= quetiapine,  Ami=amitriptyline, norAmi= noramitriptyline, Venlaf= venlafaxine, 415 
Diaz= diazepam, norDaz= nordiazepam. 416 
 417 
 418 
 419 
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The measured BCFbrain values of pharmaceuticals in the summed brain regions were 3-40 fold 420 
higher than measured BCFsplasma and ranged from 0.7 for venlafaxine to 1581 for 421 
norsertraline, indicating efficient transport and uptake into brain tissues. Similar BCFbrain 422 
values and brain/plasma concentration ratios of SSRIs have been reported in fish exposed to 423 
WwTW effluents (Grabicova et al., 2014; Lajeunesse et al., 2011; Tanoue et al., 2015).  In 424 
our study, compounds such as paroxetine, clozapine and quetiapine did not bioconcentrate in 425 
the plasma (BCFs<1), but these compounds were quantified at higher concentrations in the 426 
brain with BCFs between 67 and 157. Our data emphasise the importance of analysing target 427 
tissues of pharmaceuticals where there is a greater potential for bioaccumulation compared 428 
with the fish blood plasma. 429 
3.3. The effect ratio (ER). 430 
Comparison of fish plasma levels with human therapeutic plasma concentrations 431 
(HtPCs) has been proposed as a technique to estimate the potential hazards of 432 
pharmaceuticals in wild fish (Huerta et al., 2016; Margiotta-Casaluci et al., 2014; Tanoue et 433 
al., 2015). The read-across hypothesis has been proposed as a first step to study the potential 434 
for adverse ecotoxicological effects due to exposure to environmental pharmaceuticals and 435 
remains to be proven for most biologically active compounds (Huggett et al., 2003; Rand-436 
Weaver et al., 2013). The ER was calculated from a range of HtPCs measured in human 437 
samples (Regenthal et al., 1999; Schulz et al., 2012) and the measured or predicted fish 438 
plasma concentrations of pharmaceuticals (Table 2). An ER≤1 indicates that the predicted 439 
drug concentration in the fish plasma is equal to or greater than the drug concentration in 440 
human plasma that elicits a therapeutic effect. Measured ER values (i.e., based on measured 441 
plasma concentrations) were generally similar to predicted values and ranged from 33-5714 442 
for all compounds, and were between 39-1282 for SSRIs. In addition, combined ERs were 443 
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calculated for the 3 SSRIs sertraline, fluoxetine and norfluoxetine by assuming an additive 444 
effect. Sertraline being the most potent, was used as the reference and relative potencies of 445 
fluoxetine and norfluoxetine to sertraline were calculated based on respective HtPCs. The 446 
calculated combined ER values for these 3 compounds ranged from 31 to 195. Norsertraline 447 
was not considered in this mixture as it has only 5–10% of the serotonin reuptake inhibitor 448 
potency of sertraline and therefore a minimal contribution to clinical effects of sertraline 449 
(Hiemke and Hartter, 2000). Based on the HtPC values, and the assumptions of the read-450 
across hypothesis, then the ER data in Table 2 would suggest that none of the 451 
pharmaceuticals would have a therapeutic effect in fish. However, it should be noted that the 452 
read-across hypothesis still has to be validated for many of the SSRIs and other neuroactive 453 
pharmaceuticals investigated in this study; that knowledge of the behavioural and other 454 
endpoints of their action in fish remain incomplete; and the effects of SSRI exposure in 455 
concert with mixtures of other neuroactive substances remains uncertain. A safety factor of 456 
1000 for ER has been proposed to take into consideration extrapolation of humans to animals, 457 
sensitivity differences, and extrapolation from mammalian to non-mammalian species 458 
(Huggett et al., 2003). The ER ranges of fluoxetine, sertraline, norfluoxetine and 459 
amitriptyline fall within this safety factor indicating that these compounds in fish should be 460 
prioritised for risk assessment studies, especially if additive effects can be expected between 461 
SSRIs. However, it should also be noted that the lower bound of ER ranges for compound 462 
such as noramitriptyline, venlafaxine and nordiazepam were below 1000, and therefore 463 
effects cannot be totally excluded for these compounds if the same HtPC values are 464 
applicable to fish. 465 
 466 
 467 
 468 
 469 
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Table 2. Human therapeutic plasma concentrations (HtPC) and effect ratio of analysed 470 
pharmaceuticals  471 
  HtPC
1
 Effect ratio fish plasma
2 
Pharmaceuticals ng/mL measured predicted 
SSRIs  
   fluoxetine 100 -500 256 - 1282 646 - 3229 
norfluoxetine 150 - 400 283 - 755 724 - 1932 
sertraline 30 -250 39 - 329 21 - 176 
norsertraline unknown - - 
citalopram  10 - 200 >500 - 10000
a
 32 - 645 
paroxetine  10 - 70 nd - 
Atypical antipsychotic 
   clozapine 300 - 800 >4286 - 10000
a
 938 - 2500 
norclozapine 100 - 300 nd - 
quetiapine 20 – 500 >667 - 16667a 143 - 3571 
Tricyclic antidepressants 
   amitriptyline 50 – 300 33 - 200  7 - 42 
noramitriptyline 60 – 300 375 - 1875 231 - 1154 
SNRI 
   venlafaxine 30 – 400 429 - 5714 58 - 770 
Benzodiazepine 
   diazepam 200 - 2000 nd - 
nordiazepam 20 – 800 39 - 1569 28 - 1121 
 472 
1
 HtPC were obtained from Regenthal et al. (1999) and Schulz et al (2012). 473 
2
Effect ratio was calculated as HtPC/Cplasma, where Cplasma in fish was an average of the 474 
measured values in the plasma or the  predicted values from mean concentrations measured in 475 
the ambient wastewater effluent. The range of effect ratios are based on the range of 476 
published HtPC values. 477 
a
 based on  Cplasma MDL value when plasma concentrations were between MDL and MQL. nd 478 
= not detected (i.e. concentrations <MDL).    479 
 480 
3.4 Neurotransmitter concentrations in the brain of control and effluent-exposed fish 481 
The concentrations of 4 neurotransmitters (serotonin, tryptophan, acetylcholine and 482 
glutamate) were measured in the four brain regions of male and female roach to investigate 483 
differences in brain chemistry between control and effluent-exposed fish. Serotonin and its 484 
precursor tryptophan were selected since SSRIs act by inhibiting the serotonin transporter in 485 
the pre-synaptic cell, which in turn leads to increased extracellular levels of serotonin in the 486 
synaptic cleft (Hiemke and Hartter, 2000). Likewise, the SNRI venlafaxine and the tricyclic 487 
antidepressants act by blocking the serotonin transporter and could impact on serotonin 488 
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concentrations in the brain. Tricyclic antidepressants also have high affinity for antagonising 489 
the muscarinic acetylcholine receptors and therefore act as potent anticholinergics (Snyder 490 
and Yamamura, 1977). Glutamate was also analysed as it is a precursor of gamma-491 
aminobutyric acid (GABA) and benzodiazepines are designed to alter behaviour by binding 492 
to GABA receptors (Brodin et al., 2013). 493 
The most abundant neurotransmitter found in the brain tissues of control or effluent 494 
exposed fish was glutamate (between 2.8-259 µg/g), followed by tryptophan (3.2-57 µg/g), 495 
acetylcholine (0.22-6.3 µg/g) and serotonin (0.04-1.1 µg/g). The concentrations of 496 
neurotransmitters detected in the brain tissues of control or effluent- exposed fish were 497 
present at similar levels to that reported in the mammalian brain (Gonzalez et al., 2011). 498 
Serotonin concentrations were also similar with those reported for different regions of the 499 
brain in rainbow trout (Sloman et al., 2005). Small but significant increases in serotonin 500 
concentrations were observed in the hypothalamus (1.9 fold, p<0.05) and the telencephalon 501 
(1.5 fold, p<0.01) in effluent-exposed male but not female roach (Figure 2). A significant 502 
decrease in glutamate (4 fold, p<0.05) and acetylcholine concentrations (2.8 fold, p<0.05) 503 
was observed for the effluent-exposed females in the hypothalamus and a significant 504 
glutamate increase (2.0-3.1 fold, p<0.05) for the effluent-exposed males and female in the 505 
hindbrain (Figures S3 and S4). A significant increase in tryptophan concentrations were also 506 
observed for the effluent-exposed males in the hypothalamus (1.7 fold, p<0.05) and the optic 507 
tectum (1.5 fold, p<0.05) (Figure S5). Our data suggests that the disruption of 508 
neurotransmitter concentrations in the brain of effluent-exposed fish is sex dependent. 509 
However, an examination of the data in Figures 2 and S3-S5 reveals that the trend in 510 
responses is similar in both sexes, and further work with increased replication is needed to 511 
determine whether there are gender specific responses to effluent exposure. It is not known 512 
whether the disruption of neurotransmitter concentrations observed in our study would lead to 513 
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changes in fish behaviour and further studies would be required to determine this. 514 
Monoaminergic systems play a crucial role in linking behaviour and physiology in fish, and 515 
brain serotonin levels can influence food intake, cognitive ability, locomotor activity and 516 
social behaviour in fish (Bisesi et al., 2014; Sloman et al., 2005; Winberg et al., 1996). In 517 
addition, serotonergic modulation in the hypothalamus similar to that observed in this study 518 
has the potential to affect sex hormones and modulate genes involved in reproductive 519 
function and behaviour in the brain of female goldfish (Mennigen et al., 2008; Prasad et al., 520 
2015). 521 
Further work is required to ascertain whether disruption of neurotransmitter levels 522 
caused by effluent exposure is due solely to exposure to the pharmaceutical mixtures 523 
analysed in this study or a result of combined exposure to other contaminants such as 524 
neurotoxic insecticides which could potentially be present in the effluent and contribute to the 525 
alteration of fish neurotransmitter levels (Tufi et al., 2016). Furthermore, our study was based 526 
on exposure to an undiluted treated effluent, which may reflect the exposure conditions of 527 
aquatic organisms in some countries where there is little or no dilution of the discharges into 528 
the receiving waters during the summer period (David et al., 2013), but would need to be 529 
conducted on diluted effluents to be representative of most ambient river environments.  530 
 531 
 532 
 533 
 534 
 535 
 536 
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 537 
  538 
  539 
Figure 2. Serotonin concentrations (µg/g) in the telencephalon (A), hypothalamus (B), optic 540 
tectum (C) and hindbrain (D) of control and effluent-exposed male and female fish (n=6). * 541 
p≤0.05. Each dot represents an individual fish within the treatment group, alongside the mean 542 
± standard error of the replicates. 543 
 544 
Conclusions  545 
This study reports for the first time that a highly complex mixture of 13 neuroactive 546 
pharmaceuticals, comprising SSRIs, SNRIs, atypical antipsychotics, tricyclic antidepressants 547 
and benzodiazepines, accumulates in multiple brain regions of fish exposed to a treated 548 
WwTW effluent. Concentrations of all pharmaceuticals were below their respective HtPCs 549 
however, disruptions in serotonin, glutamate and acetylcholine concentrations were observed 550 
in different brain regions of effluent-exposed fish. Future risk assessment studies should be 551 
based on understanding the effects of exposure to these complex chemical mixtures on fish 552 
behaviour and physiology, particularly as future anthropogenic pressures are likely to result 553 
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in increased pharmaceutical exposures and fluctuating hydrological conditions in river 554 
waters.  555 
Supporting Information. Supporting information comprises UHPLC-MS/MS acquisition 556 
parameters; MDL, MQL and method recoveries for neurotransmitter and pharmaceutical 557 
compounds in extracts of brain tissues, plasma and water and additional tables and figures 558 
with pharmaceutical and neurotransmitter concentrations in WwTW effluents, plasma and 559 
brain tissues.  560 
 561 
ACKNOWLEDGMENT 562 
This research was supported by a Marie Curie Intra European Fellowship within the 563 
European Community Seventh Framework Programme ([FP7/2007-2013]) under grant 564 
agreement no: 302097. We gratefully acknowledge the fish team at Exeter University and 565 
J.A. Shears in particular as well as Andrew Chetwynd (University of Sussex) and Victoria 566 
Jennings (University of Exeter) for help during the effluent exposure experiment. 567 
 568 
REFERENCES 569 
Barry, M.J.,  2013. Effects of fluoxetine on the swimming and behavioural responses of the 570 
Arabian killifish. Ecotoxicology. 22, 425-32. 571 
Bisesi, J.H., Jr., Bridges, W., Klaine, S.J.,  2014. Effects of the antidepressant venlafaxine on 572 
fish brain serotonin and predation behavior. Aquatic Toxicology. 148, 130-8. 573 
Brodin, T., Fick, J., Jonsson, M., Klaminder, J.,  2013. Dilute concentrations of a psychiatric 574 
drug alter behavior of fish from natural populations. Science. 339, 814-5. 575 
Brooks, B.W., Chambliss, C.K., Stanley, J.K., Ramirez, A., Banks, K.E., Johnson, R.D., 576 
Lewis, R.J.,  2005. Determination of select antidepressants in fish from an effluent-577 
dominated stream. Environmental Toxicology and Chemistry. 24, 464-469. 578 
David, A., Lange, A., Abdul-Sada, A., Tyler, C.R., Hill, E.M.,  2017. Disruption of the 579 
Prostaglandin Metabolome and Characterization of the Pharmaceutical Exposome in 580 
Fish Exposed to Wastewater Treatment Works Effluent As Revealed by Nanoflow-581 
Nanospray Mass Spectrometry-Based Metabolomics. Environmental Science & 582 
Technology. 51, 616-624. 583 
David, A., Tournoud, M.G., Perrin, J.L., Rosain, D., Rodier, C., Salles, C., Bancon-584 
Montigny, C., Picot, B.,  2013. Spatial and temporal trends in water quality in a 585 
 27 
Mediterranean temporary river impacted by sewage effluents. Environmental 586 
Monitoring and Assessment. 185, 2517-34. 587 
Dzieweczynski, T.L., Hebert, O.L.,  2012. Fluoxetine alters behavioral consistency of 588 
aggression and courtship in male Siamese fighting fish, Betta splendens. Physiology 589 
& Behavior. 107, 92-7. 590 
Fent, K., Weston, A.A., Caminada, D.,  2006. Ecotoxicology of human pharmaceuticals. 591 
Aquatic Toxicology. 76, 122-59. 592 
Friedman, H., Abernethy, D.R., Greenblatt, D.J., Shader, R.I.,  1986. The pharmacokinetics 593 
of diazepma and desmethyldiazepam in rat brain and plasma. Psychopharmacology. 594 
88, 267-270. 595 
Gardner, M., Comber, S., Scrimshaw, M.D., Cartmell, E., Lester, J., Ellor, B.,  2012. The 596 
significance of hazardous chemicals in wastewater treatment works effluents. Science 597 
of the Total Environment. 437, 363-72. 598 
Gonzalez, R.R., Fernandez, R.F., Vidal, J.L., Frenich, A.G., Perez, M.L.,  2011. Development 599 
and validation of an ultra-high performance liquid chromatography-tandem mass-600 
spectrometry (UHPLC-MS/MS) method for the simultaneous determination of 601 
neurotransmitters in rat brain samples. Journal of Neuroscience Methods. 198, 187-602 
94. 603 
Grabicova, K., Lindberg, R.H., Ostman, M., Grabic, R., Randak, T., Larsson, D.G., Fick, J.,  604 
2014. Tissue-specific bioconcentration of antidepressants in fish exposed to effluent 605 
from a municipal sewage treatment plant. Science of The Total Environment. 488-606 
489, 46-50. 607 
Hiemke, C., Hartter, S.,  2000. Pharmacokinetics of selective serotonin reuptake inhibitors. 608 
Pharmacology & Therapeutics. 85, 11-28. 609 
Huerta, B., Margiotta-Casaluci, L., Rodriguez-Mozaz, S., Scholze, M., Winter, M.J., Barcelo, 610 
D., Sumpter, J.P.,  2016. Anti-anxiety drugs and fish behaviour: Establishing the link 611 
between internal concentrations of oxazepam and behavioural effects. Environmental 612 
Toxicology and Chemistry. 613 
Huggett, D.B., Cook, J.C., Ericson, J.F., Williams, R.T.,  2003. A theoretical model for 614 
utilizing mammalian pharmacology and safety data to prioritize potential impacts of 615 
human pharmaceuticals to fish. Human and Ecological Risk Assessment. 9, 1789-616 
1799. 617 
Kellner, M., Porseryd, T., Hallgren, S., Porsch-Hällström, I., Hansen, S.H., Olsén, K.H.,  618 
2016b. Waterborne citalopram has anxiolytic effects and increases locomotor activity 619 
in the three-spine stickleback (Gasterosteus aculeatus). Aquatic Toxicology. 173, 19-620 
28. 621 
Kostich, M.S., Batt, A.L., Lazorchak, J.M.,  2014. Concentrations of prioritized 622 
pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and 623 
implications for risk estimation. Environmental Pollution. 184, 354-9. 624 
Lajeunesse, A., Gagnon, C., Gagne, F., Louis, S., Cejka, P., Sauve, S.,  2011. Distribution of 625 
antidepressants and their metabolites in brook trout exposed to municipal wastewaters 626 
before and after ozone treatment - Evidence of biological effects. Chemosphere. 83, 627 
564-571. 628 
Margiotta-Casaluci, L., Owen, S.F., Cumming, R.I., de Polo, A., Winter, M.J., Panter, G.H., 629 
Rand-Weaver, M., Sumpter, J.P.,  2014. Quantitative Cross-Species Extrapolation 630 
between Humans and Fish: The Case of the Anti-Depressant Fluoxetine. Plos One. 9. 631 
McCallum, E.S., Krutzelmann, E., Brodin, T., Fick, J., Sundelin, A., Balshine, S.,  2017. 632 
Exposure to wastewater effluent affects fish behaviour and tissue-specific uptake of 633 
pharmaceuticals. Science of The Total Environment. 605-606, 578-588. 634 
 28 
Mennigen, J.A., Martyniuk, C.J., Crump, K., Xiong, H., Zhao, E., Popesku, J., Anisman, H., 635 
Cossins, A.R., Xia, X., Trudeau, V.L.,  2008. Effects of fluoxetine on the reproductive 636 
axis of female goldfish (Carassius auratus). Physiological Genomics. 35, 273-82. 637 
Nallani, G., Venables, B., Constantine, L., Huggett, D.,  2016. Comparison of Measured and 638 
Predicted Bioconcentration Estimates of Pharmaceuticals in Fish Plasma and 639 
Prediction of Chronic Risk. Bulletion of Environmental Contamination and 640 
Toxicology. 96, 580-4. 641 
Overturf, C.L., Overturf, M.D., Huggett, D.B.,  2016. Bioconcentration and endocrine 642 
disruption effects of diazepam in channel catfish, Ictalurus punctatus. Comparative 643 
Biochemistry and Physiology Part C: Toxicology & Pharmacology. 183-184, 46-52. 644 
Paterson, G., Metcalfe, C.D.,  2008. Uptake and depuration of the anti-depressant fluoxetine 645 
by the Japanese medaka (Oryzias latipes). Chemosphere. 74, 125-30. 646 
Petrie, B., Barden, R., Kasprzyk-Hordern, B.,  2015. A review on emerging contaminants in 647 
wastewaters and the environment: current knowledge, understudied areas and 648 
recommendations for future monitoring. Water Research. 72, 3-27. 649 
Prasad, P., Ogawa, S., Parhar, I.S.,  2015. Role of serotonin in fish reproduction. Frontiers in 650 
Neuroscience. 9, 195. 651 
Rand-Weaver, M., Margiotta-Casaluci, L., Patel, A., Panter, G.H., Owen, S.F., Sumpter, J.P.,  652 
2013. The Read-Across Hypothesis and Environmental Risk Assessment of 653 
Pharmaceuticals. Environmental Science & Technology. 47, 11384-11395. 654 
Regenthal, R., Krueger, M., Koeppel, C., Preiss, R.,  1999. Drug levels: therapeutic and toxic 655 
serum/plasma concentrations of common drugs. Journal of Clinical Monitoring and 656 
Computing. 15, 529-44. 657 
Schulz, M., Iwersen-Bergmann, S., Andresen, H., Schmoldt, A.,  2012. Therapeutic and toxic 658 
blood concentrations of nearly 1,000 drugs and other xenobiotics. Critical Care. 16, 659 
R136. 660 
Sloman, K.A., Lepage, O., Rogers, J.T., Wood, C.M., Winberg, S.,  2005. Socially-mediated 661 
differences in brain monoamines in rainbow trout: effects of trace metal contaminants. 662 
Aquatic Toxicology. 71, 237-47. 663 
Snyder, S.H., Yamamura, H.I.,  1977. Antidepressants and the muscarinic acetylcholine 664 
receptor. Archives of General Psychiatry. 34, 236-9. 665 
Sumpter, J.P., Donnachie, R.L., Johnson, A.C.,  2014. The apparently very variable potency 666 
of the anti-depressant fluoxetine. Aquatic Toxicology. 151, 57-60. 667 
Tanoue, R., Nomiyama, K., Nakamura, H., Kim, J.W., Isobe, T., Shinohara, R., Kunisue, T., 668 
Tanabe, S.,  2015. Uptake and Tissue Distribution of Pharmaceuticals and Personal 669 
Care Products in Wild Fish from Treated-Wastewater-Impacted Streams. 670 
Environmental Science & Technology. 49, 11649-11658. 671 
Tufi, S., Leonards, P., Lamoree, M., de Boer, J., Legler, J., Legradi, J.,  2016. Changes in 672 
Neurotransmitter Profiles during Early Zebrafish (Danio rerio) Development and 673 
after Pesticide Exposure. Environmental Science & Technology. 50, 3222-30. 674 
Valenti, T.W., Gould, G.G., Berninger, J.P., Connors, K.A., Keele, N.B., Prosser, K.N., 675 
Brooks, B.W.,  2012. Human therapeutic plasma levels of the selective serotonin 676 
reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding 677 
and shelter-seeking behavior in adult male fathead minnows. Environmental Science 678 
& Technology. 46, 2427-35. 679 
Valenti, T.W., Jr., Perez-Hurtado, P., Chambliss, C.K., Brooks, B.W.,  2009. Aquatic toxicity 680 
of sertraline to Pimephales promelas at environmentally relevant surface water pH. 681 
Environmental Toxicology and Chemistry. 28, 2685-94. 682 
Wille, S.M.R., De Letter, E.A., Piette, M.H.A., Van Overschelde, L.K., Van Peteghem, C.H., 683 
Lambert, W.E.,  2009. Determination of antidepressants in human postmortem blood, 684 
 29 
brain tissue, and hair using gas chromatography-mass spectrometry. International 685 
Journal of Legal Medicine. 123, 451-458. 686 
Winberg, S., Myrberg, A.A., Jr., Nilsson, G.E.,  1996. Agonistic interactions affect brain 687 
serotonergic activity in an acanthopterygiian fish: the bicolor damselfish 688 
(Pomacentrus partitus). Brain, Behavior and Evolution. 48, 213-20. 689 
Xie, Z., Lu, G., Li, S., Nie, Y., Ma, B., Liu, J.,  2015. Behavioral and biochemical responses 690 
in freshwater fish Carassius auratus exposed to sertraline. Chemosphere. 135, 146-691 
55. 692 
Ziarrusta, H., Mijangos, L., Izagirre, U., Plassmann, M.M., Benskin, J.P., Anakabe, E., 693 
Olivares, M., Zuloaga, O.,  2017. Bioconcentration and Biotransformation of 694 
Amitriptyline in Gilt-Head Bream. Environmental Science & Technology. 51, 2464-695 
2471. 696 
 697 
 698 
 699 
